Payment overview · 2025
General Payments
$251.78
9 reported records · 5 companies
Healthcare provider profile · identity verified
Rick Waks, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FORT MYERS, FL · NPI 1194726091
Verified facts
What the public records show
CMS Open Payments records show Rick Waks, D.O. received $251.78 in general payments during 2025 across 9 reported records.
Dexcom, Inc. accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.00 | 35.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.00 | 26.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.46 | 19.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.42 | 9.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.90 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.78 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $43.81 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 737 | 204 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 101 |
| Metformin Hcl | Metformin Hcl | 338 | 98 |
| Lisinopril | Lisinopril | 336 | 100 |
| Losartan Potassium | Losartan Potassium | 272 | 80 |
| Omeprazole | Omeprazole | 223 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 54 |
| Simvastatin | Simvastatin | 178 | 47 |
| Trazodone Hcl | Trazodone Hcl | 176 | 52 |
| Gabapentin | Gabapentin | 167 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 44 |
| Sertraline Hcl | Sertraline Hcl | 163 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 41 |
| Atenolol | Atenolol | 143 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 33 |
| Allopurinol | Allopurinol | 119 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 33 |
| Clonazepam | Clonazepam | 112 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 21 |
| Ezetimibe | Ezetimibe | 103 | 27 |
| Ozempic | Semaglutide | 103 | 24 |
| Furosemide | Furosemide | 101 | 31 |
| Carvedilol | Carvedilol | 96 | 27 |
| Alprazolam | Alprazolam | 95 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 23 |
| Meloxicam | Meloxicam | 89 | 31 |
| Prednisone | Prednisone | 88 | 68 |
| Montelukast Sodium | Montelukast Sodium | 80 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 30 |
| Famotidine | Famotidine | 67 | 23 |
| Eliquis | Apixaban | 54 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 13 |
| Potassium Chloride | Potassium Chloride | 52 | 14 |
| Azithromycin | Azithromycin | 50 | 48 |
| Jardiance | Empagliflozin | 50 | 14 |
| Lorazepam | Lorazepam | 50 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Glipizide | Glipizide | 49 | 15 |
| Finasteride | Finasteride | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 35 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Telmisartan | Telmisartan | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 13 |
| Spironolactone | Spironolactone | 37 | 11 |
| Lovastatin | Lovastatin | 36 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Baclofen | Baclofen | 34 | 23 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 20 |
| Valsartan | Valsartan | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Torsemide | Torsemide | 22 | 11 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.78 · 9 records | Dexcom, Inc. | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error